Thus, NSCLC patients with KRAS mutations are likely to have a worse outcome, even if they are treated with immunotherapy as their first-line therapy, regardless of whether they have high or low levels of PDL1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.